New cell therapy aims to make stem cell transplants safer for blood cancer patients

NCT ID NCT07216443

Recruiting now Disease control Sponsor: Orca Biosystems, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This phase 2 trial is testing a new treatment called Orca-T for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Orca-T is a personalized cell therapy made from a donor's blood that includes stem cells and immune cells. The goal is to see if it can improve transplant success and reduce serious side effects like graft-versus-host disease. About 80 adults will take part in the study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Orca-T (a stem cell and T-cell therapy made from a donor's blood)
What this could lead to: If successful, Orca-T could offer a safer and more effective stem cell transplant option for people with blood cancers, reducing the risk of graft-versus-host disease and relapse.
What could go wrong: This is an early-phase trial with only 80 participants, so results may not apply to everyone. There are risks of infection, graft failure, or severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute disease acute myeloid leukemia bone marrow disorder disease Disease Attributes graft versus host disease hematologic disorder hematopoietic and lymphoid system neoplasm immune system disorder immunoproliferative disorder leukemia mixed phenotype acute leukemia myelodysplastic syndrome Myelodysplastic Syndromes neoplasm Neoplasms by Histologic Type Neoplasms by Site Pathologic Processes precancerous condition Preleukemia syndromic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE MIXED PHENOTYPE ACUTE LEUKEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

John Theurer Cancer Center at Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Oregon Health and Science University
RECRUITING

Portland, Oregon, 97239, United States
UCLA Department of Medicine
RECRUITING

Los Angeles, California, 90095, United States
Vanderbilt University, Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States
Weill Cornell Medicine - New York Presbyterian Hospital
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.